Spero Therapeutics, Inc. Operating Lease, Payments
Spero Therapeutics, Inc. (SPRO) reported Operating Lease, Payments of $1.75 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-03-26
- Spero Therapeutics, Inc. operating lease, payments for the quarter ending 2020-12-31 was $378.00K, a 65.79% increase year-over-year.
- Spero Therapeutics, Inc. operating lease, payments for the quarter ending 2020-09-30 was $330.00K, a 11.76% decline year-over-year.
- Spero Therapeutics, Inc. operating lease, payments for the quarter ending 2020-06-30 was $231.00K, a 26.90% decline year-over-year.
- Spero Therapeutics, Inc. operating lease, payments for the quarter ending 2020-03-31 was $232.00K, a 26.58% decline year-over-year.
- Spero Therapeutics, Inc. operating lease, payments for fiscal 2025 was $1.75M, a 1.63% increase from fiscal 2024.
- Spero Therapeutics, Inc. operating lease, payments for fiscal 2024 was $1.72M, a 1.66% increase from fiscal 2023.
- Spero Therapeutics, Inc. operating lease, payments for fiscal 2023 was $1.69M, a 11.62% increase from fiscal 2022.
- Spero Therapeutics, Inc. operating lease, payments for fiscal 2022 was $1.51M, a 0.72% decline from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.75M 10-K · filed 2026-03-26 | |||
| 2024-12-31 | $1.72M 10-K · filed 2026-03-26 | |||
| 2023-12-31 | $1.69M 10-K · filed 2025-03-27 | |||
| 2022-12-31 | $1.51M 10-K · filed 2024-03-13 | |||
| 2021-12-31 | $1.52M 10-K · filed 2023-03-30 | |||
| 2020-12-31 | $378.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $708.00K derived: sum of 2 quarters · filed 2022-03-31 | $939.00K derived: sum of 3 quarters · filed 2022-03-31 | $1.17M 10-K · filed 2022-03-31 |
| 2020-09-30 | $330.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $561.00K derived: sum of 2 quarters · filed 2020-11-05 | $793.00K 10-Q · filed 2020-11-05 | $1.02M derived: sum of 4 quarters · filed 2021-03-11 |
| 2020-06-30 | $231.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $463.00K 10-Q · filed 2020-08-06 | $691.00K derived: sum of 3 quarters · filed 2021-03-11 | $1.06M derived: sum of 4 quarters · filed 2021-03-11 |
| 2020-03-31 | $232.00K 10-Q · filed 2020-05-08 | $460.00K derived: sum of 2 quarters · filed 2021-03-11 | $834.00K derived: sum of 3 quarters · filed 2021-03-11 | $1.15M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-12-31 | $228.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $602.00K derived: sum of 2 quarters · filed 2021-03-11 | $918.00K derived: sum of 3 quarters · filed 2021-03-11 | $1.23M 10-K · filed 2021-03-11 |
| 2019-09-30 | $374.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $690.00K derived: sum of 2 quarters · filed 2019-11-04 | $1.01M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $316.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $632.00K 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $316.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |